The first five months of the year showed a slight increase in U.S. FDA approvals, though numbers are down compared to the previous four years. Worldwide approvals are down 16.67% through May, but up 5.42% compared to the previous seven years’ average.
Biopharma deal values are continuing to track at a similar pace to last year, down only 0.31% compared to the first five months of 2022, while there have been 173 fewer deals. M&A values are at their lowest value in all years tracked by BioWorld (2016-2023).
In the first five months of 2023, med-tech deal value is at the highest amount in recent years – up 128.219% from last year – while deal volume has decreased by 12.29%. Through May this year, 742 med-tech deals have raised a potential $5.38 billion, compared to 846 deals totalling $2.36 billion last year. The two recent years are vastly more than 2021, when through May there were 661 deals raising $386.69 million.
RSS
